Compare Moderna, Inc. (MRNA) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Toronto-Dominion Bank — how do they compare? Moderna, Inc. trades at $135.9 (market cap $56.02B), while Toronto-Dominion Bank trades at $119.29 (market cap $197.22B). The key difference: Toronto-Dominion Bank is far larger — about 3.5× Moderna, Inc.'s market cap, and Toronto-Dominion Bank pays a 2.69% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | TD | |
|---|---|---|
Market Cap | $56.02B | $197.22B |
Sector | Health | Financials |
52-Week High | $174.38 | $124.80 |
52-Week Low | $22.36 | $75.86 |
Enterprise Value | $52.17B | — |
Dividend Yield | — | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
TD trades at $120.52, down 0.91% on the day, with a neutral technical signal. The company reported strong Q3 2026 earnings of $2.74 EPS, beating estimates, driven by capital markets performance and cost controls. Revenue growth continues with 2025 revenue reaching $61.28B and net income margin of 33.51%. Analyst consensus is bullish with 9 buy ratings and no sell recommendations.
TD presents a compelling investment case with consistent earnings beats and strong profitability metrics. However, investors should monitor the volatile cash flow patterns and rising debt-to-asset ratio, which increased to 22.1 in 2024. The stock's current valuation at 17.85 P/E appears reasonable given the company's growth trajectory and dividend yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
